ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC Wainwright

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $21.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 270.37% from the stock's current price.

A number of other analysts have also weighed in on ORIC. Wedbush reiterated an "outperform" rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Guggenheim reissued a "buy" rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. upped their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $18.86.

ORIC Pharmaceuticals Stock Performance

Shares of ORIC opened at $5.67 on Monday. The stock has a 50-day moving average of $6.17 and a two-hundred day moving average of $8.19. The stock has a market cap of $403.05 million, a P/E ratio of -3.12 and a beta of 1.37. ORIC Pharmaceuticals has a one year low of $3.90 and a one year high of $14.67.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.01. Analysts predict that ORIC Pharmaceuticals will post -2.17 EPS for the current fiscal year.

Institutional Trading of ORIC Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ORIC. KLP Kapitalforvaltning AS acquired a new position in ORIC Pharmaceuticals during the 4th quarter worth $50,000. Arizona State Retirement System acquired a new position in shares of ORIC Pharmaceuticals during the first quarter worth about $56,000. BNP Paribas Financial Markets purchased a new stake in shares of ORIC Pharmaceuticals during the fourth quarter worth approximately $71,000. PNC Financial Services Group Inc. raised its holdings in ORIC Pharmaceuticals by 22.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after acquiring an additional 2,520 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in ORIC Pharmaceuticals by 1,048.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 14,661 shares of the company's stock worth $118,000 after acquiring an additional 13,384 shares during the last quarter. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.